With venture capital investment in biotech rising by 33% in 2024, investors are looking beyond traditional models and toward emerging therapeutic breakthroughs and scalable platform technologies. But with many companies still in preclinical or early clinical stages, identifying real opportunities requires more than just capital.
At RESI Europe 2025, taking place in Barcelona on April 1, Artemy Shumskiy, Senior Associate at LongeVC, will join a panel alongside Carla Benichou (RV Invest), Laura Rodríguez Gallego (Invivo Partners), and moderator Jim McGough (Mid Atlantic Bio Angels) to discuss biotech investment strategies, risk assessment, and the role of investors and in-licensing partners in scaling platform technologies across multiple indications.
For those attending RESI Europe, this panel will offer insights into the evolving biotech investment landscape and the factors shaping the next wave of therapeutic innovation. If you're in Barcelona and would like to connect, feel free to reach out to Artemy via LinkedIn or email us at hq@longevc.com.
Learn more about the event here.
At RESI Europe 2025, taking place in Barcelona on April 1, Artemy Shumskiy, Senior Associate at LongeVC, will join a panel alongside Carla Benichou (RV Invest), Laura Rodríguez Gallego (Invivo Partners), and moderator Jim McGough (Mid Atlantic Bio Angels) to discuss biotech investment strategies, risk assessment, and the role of investors and in-licensing partners in scaling platform technologies across multiple indications.
For those attending RESI Europe, this panel will offer insights into the evolving biotech investment landscape and the factors shaping the next wave of therapeutic innovation. If you're in Barcelona and would like to connect, feel free to reach out to Artemy via LinkedIn or email us at hq@longevc.com.
Learn more about the event here.